RegulatoryApr 22, 2026, 08:07 AM
Incannex PSX-001 Program Aligns with White House Psychedelic Order
AI Summary
Incannex Healthcare Inc. announced that its PSX-001 oral synthetic psilocybin program aligns with a recent White House Executive Order. The order, signed by President Donald J. Trump on April 18, 2026, aims to accelerate access to psychedelic treatments for serious mental illness. This development is expected to significantly improve the regulatory environment for Incannex's program, potentially expediting its advancement.
Key Highlights
- Incannex Healthcare's PSX-001 program focuses on oral synthetic psilocybin.
- The program aligns with a White House Executive Order signed April 18, 2026.
- The Executive Order aims to accelerate access to psychedelic treatments for serious mental illness.
- This alignment is expected to improve the regulatory environment for Incannex's program.
Price Impact
More from IXHL